The high levels of CD4+ T cells producing IL-10 were described in asymptomatic carriers as a possible immunoregulatory mechanism that guarantees their asymptomatic clinical status (49), and IL-10 blockage in ATLL patients collaborates with leukemia-initiating cell eradication (32). This evidence concerns the gene IL10 and leukemia.